# Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

> **NCT04221906** · PHASE1 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** BOS-475
- **DRUG:** Active ingredient-free vehicle cream
- **DRUG:** Daivonex cream (calcipotriol 0.005%)
- **DRUG:** Betnesol-V cream (betamethasone 0.1%)

## Key facts

- **NCT ID:** NCT04221906
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-06
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-03-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221906, "Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04221906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*